• Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass…

  • Comprehensive Research from West China Hospital of Sichuan University

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) was held in San Francisco, USA, from February 16th to 18th, 2023. Dr. Qiang Wei and Dr. Hao Zeng’s team had multiple findings selected for academic exchange at this ASCO-GU symposium. Their work addressed prostate cancer, urinary tract carcinoma, and kidney cancer, covering…

  • Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients

    Fudan University Shanghai Cancer Center Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao’s team suggests that among patients receiving different treatment regimens, Asian males have superior…

  • Urinary Tumor DNA for MRD Detection in NMIBC rTURBT

    The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off in San Francisco on February 16, 2023. On the second day of the conference, during a special session on urothelial carcinoma, Professor Kyle M. Rose from the H. Lee Moffitt Cancer Center presented a prospective study on using cfDNA/utDNA for MRD detection…

  • Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis…

  • Dr. Kan Gong: Research Progress in ASCO-GU 2023 Kidney Cancer

    The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of kidney cancer diagnosis, a novel molecular imaging agent, 89Zr-DFO-girentuximab, has been shown to accurately diagnose clear cell renal cell carcinoma (ccRCC). In the first-line treatment area, the CheckMate 9ER study…

  • Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer

    Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating…

  • Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation  

    The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer;…